US20040122000A1
(en)
*
|
1981-01-07 |
2004-06-24 |
Vertex Pharmaceuticals Incorporated. |
Inhibitors of aspartyl protease
|
UA59384C2
(uk)
*
|
1996-12-20 |
2003-09-15 |
Пфайзер, Інк. |
Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
|
US6436989B1
(en)
*
|
1997-12-24 |
2002-08-20 |
Vertex Pharmaceuticals, Incorporated |
Prodrugs of aspartyl protease inhibitors
|
US6686366B1
(en)
|
1998-06-02 |
2004-02-03 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
US6878716B1
(en)
|
1998-06-02 |
2005-04-12 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptor and uses thereof
|
ID27600A
(id)
|
1998-06-02 |
2001-04-12 |
Osi Pharm Inc |
KOMPOSISI PIROLO (2,3d) PIRIMIDIN DAN PENGGUNAANNYA
|
GB9815567D0
(en)
*
|
1998-07-18 |
1998-09-16 |
Glaxo Group Ltd |
Antiviral compound
|
AU6329599A
(en)
*
|
1998-09-28 |
2000-04-17 |
Glaxo Group Limited |
Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester
|
GB9914821D0
(en)
*
|
1999-06-24 |
1999-08-25 |
Glaxo Group Ltd |
Compounds
|
US6680322B2
(en)
|
1999-12-02 |
2004-01-20 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptors and uses thereof
|
US7160890B2
(en)
|
1999-12-02 |
2007-01-09 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
US6664252B2
(en)
|
1999-12-02 |
2003-12-16 |
Osi Pharmaceuticals, Inc. |
4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
|
US6680324B2
(en)
|
2000-12-01 |
2004-01-20 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptors and uses thereof
|
US6673802B2
(en)
|
2000-12-01 |
2004-01-06 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
KR100870184B1
(ko)
|
2001-02-14 |
2008-11-24 |
티보텍 파마슈티칼즈 리미티드 |
광범위 2-(치환된-아미노)-벤조티아졸 설폰아미드 hiv프로티아제 억제제
|
AR035819A1
(es)
|
2001-04-09 |
2004-07-14 |
Tibotec Pharm Ltd |
2-(amino sustituido)-benzoxazol sulfonamidas, inhibidoras de la proteasa del hiv, composiciones farmaceuticas que comprenden dichos compuestos, metodo in vitro para inhibir la replicacion retroviral y uso de dichos compuestos en la fabricacion de medicamentos
|
AU2002310818B2
(en)
|
2001-05-11 |
2007-12-13 |
Tibotec Pharmaceuticals Ltd. |
Broadspectrum 2-amino-benzoxazole sulfonamide HIV protease inhibitors
|
US7576084B2
(en)
*
|
2001-10-12 |
2009-08-18 |
Choongwae Pharma Corporation |
Reverse-turn mimetics and method relating thereto
|
US7504407B2
(en)
|
2001-11-30 |
2009-03-17 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 and A3 receptors and uses thereof
|
AR037797A1
(es)
*
|
2001-12-12 |
2004-12-01 |
Tibotec Pharm Ltd |
Combinacion de inhibidores de proteasa dependientes del citocromo p450
|
EA007468B1
(ru)
|
2001-12-20 |
2006-10-27 |
Оси Фармасьютикалз, Инк. |
Пиримидиновые соединения, относящиеся к a-селективным антагонистам, их синтез и применение
|
CN1816551A
(zh)
|
2001-12-20 |
2006-08-09 |
Osi药物公司 |
吡咯并嘧啶A2b选择性拮抗剂化合物,它们的合成及用途
|
EA009556B1
(ru)
|
2001-12-21 |
2008-02-28 |
Тиботек Фармасьютикалз Лтд. |
Гетероциклические замещённые фенилсодержащие сульфонамиды широкого спектра действия в качестве ингибиторов протеазы вич
|
MY142238A
(en)
|
2002-03-12 |
2010-11-15 |
Tibotec Pharm Ltd |
Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
|
US7157489B2
(en)
*
|
2002-03-12 |
2007-01-02 |
The Board Of Trustees Of The University Of Illinois |
HIV protease inhibitors
|
CA2481449A1
(en)
*
|
2002-04-26 |
2003-11-06 |
Gilead Sciences, Inc. |
Method and compositions for identifying anti-hiv therapeutic compounds
|
KR101019648B1
(ko)
|
2002-05-17 |
2011-03-07 |
티보텍 파마슈티컬즈 |
광범위 스펙트럼의 치환된 벤즈이속사졸 설폰아미드hiv 프로테아제 저해제
|
PL375307A1
(en)
|
2002-08-14 |
2005-11-28 |
Tibotec Pharmaceuticals Ltd. |
Broadspectrum substituted oxindole sulfonamide hiv protease inhibitors
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
CA2425031A1
(en)
*
|
2003-04-01 |
2004-10-01 |
Smithkline Beecham Corporation |
Pharmaceutical compositions
|
EP1620109A2
(en)
|
2003-04-25 |
2006-02-01 |
Gilead Sciences, Inc. |
Kinase inhibitor phosphonate conjugates
|
US7407965B2
(en)
|
2003-04-25 |
2008-08-05 |
Gilead Sciences, Inc. |
Phosphonate analogs for treating metabolic diseases
|
US7470724B2
(en)
|
2003-04-25 |
2008-12-30 |
Gilead Sciences, Inc. |
Phosphonate compounds having immuno-modulatory activity
|
US7452901B2
(en)
|
2003-04-25 |
2008-11-18 |
Gilead Sciences, Inc. |
Anti-cancer phosphonate analogs
|
US7432261B2
(en)
|
2003-04-25 |
2008-10-07 |
Gilead Sciences, Inc. |
Anti-inflammatory phosphonate compounds
|
PL1628685T3
(pl)
|
2003-04-25 |
2011-05-31 |
Gilead Sciences Inc |
Przeciwwirusowe analogi fosfonianowe
|
WO2005002626A2
(en)
|
2003-04-25 |
2005-01-13 |
Gilead Sciences, Inc. |
Therapeutic phosphonate compounds
|
US7427636B2
(en)
|
2003-04-25 |
2008-09-23 |
Gilead Sciences, Inc. |
Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
|
US7300924B2
(en)
|
2003-04-25 |
2007-11-27 |
Gilead Sciences, Inc. |
Anti-infective phosphonate analogs
|
EP2298323A3
(en)
|
2003-07-09 |
2011-05-11 |
Paratek Pharmaceuticals, Inc. |
Substituted tetracycline compounds
|
US20050137174A1
(en)
*
|
2003-07-09 |
2005-06-23 |
Paratek Pharmaceuticals, Inc. |
Prodrugs of 9-aminomethyl tetracycline compounds
|
US20050119163A1
(en)
*
|
2003-09-18 |
2005-06-02 |
The Government Of The United States Of America, As Represented By The Secretary, |
SH2 domain binding inhibitors
|
US7432273B2
(en)
|
2003-10-24 |
2008-10-07 |
Gilead Sciences, Inc. |
Phosphonate analogs of antimetabolites
|
WO2005044279A1
(en)
|
2003-10-24 |
2005-05-19 |
Gilead Sciences, Inc. |
Purine nucleoside phosphonate conjugates
|
US20050131042A1
(en)
*
|
2003-12-11 |
2005-06-16 |
Flentge Charles A. |
HIV protease inhibiting compounds
|
US8193227B2
(en)
|
2003-12-11 |
2012-06-05 |
Abbott Laboratories |
HIV protease inhibiting compounds
|
US7834043B2
(en)
*
|
2003-12-11 |
2010-11-16 |
Abbott Laboratories |
HIV protease inhibiting compounds
|
CN102627609B
(zh)
*
|
2003-12-15 |
2016-05-04 |
默沙东公司 |
杂环天冬氨酰蛋白酶抑制剂
|
US7799772B2
(en)
|
2003-12-18 |
2010-09-21 |
Janssen Pharmaceutica N.V. |
Pyrido-and pyrimidopyrimidine derivatives as anti-profilerative agents
|
WO2005063751A1
(en)
|
2003-12-22 |
2005-07-14 |
Gilead Sciences, Inc. |
4’-substituted carbovir-and abacavir-derivatives as well as related compounds with hiv and hcv antiviral activity
|
US7718633B2
(en)
*
|
2004-07-06 |
2010-05-18 |
Abbott Laboratories |
Prodrugs of HIV protease inhibitors
|
DK1778251T3
(da)
|
2004-07-27 |
2011-07-18 |
Gilead Sciences Inc |
Nukleosidphosphatkonjugater som anti-HIV-midler
|
US7388008B2
(en)
*
|
2004-08-02 |
2008-06-17 |
Ambrilia Biopharma Inc. |
Lysine based compounds
|
BRPI0418651A
(pt)
*
|
2004-08-02 |
2007-05-29 |
Ambrilia Biopharma Inc |
compostos com base em lisina
|
EP1789107B1
(en)
|
2004-08-30 |
2009-05-27 |
Interstitial Therapeutics |
Medical stent provided with inhibitors of atp synthesis
|
CN101098698A
(zh)
|
2004-12-01 |
2008-01-02 |
德福根有限公司 |
与离子通道尤其是Kv家族离子通道相互作用的5-羧酰胺基取代的噻唑衍生物
|
NI200700147A
(es)
|
2004-12-08 |
2019-05-10 |
Janssen Pharmaceutica Nv |
Derivados de quinazolina inhibidores de cinasas dirigidos a multip
|
JP4326575B2
(ja)
|
2004-12-17 |
2009-09-09 |
デブゲン・エヌ・ブイ |
殺線虫性組成物
|
AU2006206458B2
(en)
*
|
2005-01-19 |
2012-10-25 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
JP2008533017A
(ja)
*
|
2005-03-11 |
2008-08-21 |
スミスクライン ビーチャム コーポレーション |
Hivプロテアーゼ阻害薬
|
AR053845A1
(es)
|
2005-04-15 |
2007-05-23 |
Tibotec Pharm Ltd |
5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
|
US20060287316A1
(en)
*
|
2005-04-27 |
2006-12-21 |
Ambrilia Biopharma Inc. |
Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors
|
WO2007045496A1
(en)
|
2005-10-21 |
2007-04-26 |
Universiteit Antwerpen |
Novel urokinase inhibitors
|
AR057182A1
(es)
|
2005-11-28 |
2007-11-21 |
Tibotec Pharm Ltd |
Compuestos de aminofenilsulfonamida sustituida como inhibidores de proteasa del vih
|
TWI432438B
(zh)
|
2005-11-28 |
2014-04-01 |
Tibotec Pharm Ltd |
作為hiv蛋白酶抑制劑之經取代的胺基苯基磺醯胺化合物及衍生物
|
PT1976877E
(pt)
|
2005-11-30 |
2014-04-29 |
Abbvie Inc |
Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
|
ES2452718T3
(es)
*
|
2005-11-30 |
2014-04-02 |
Taimed Biologics, Inc. |
Profármacos a base de lisina de inhibidores de la aspartil proteasa y procesos para su preparación
|
EP1954718B1
(en)
|
2005-11-30 |
2014-09-03 |
AbbVie Inc. |
Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
|
JP4644287B2
(ja)
*
|
2005-12-27 |
2011-03-02 |
大塚製薬株式会社 |
水溶性ベンゾアゼピン化合物及び医薬組成物
|
AU2007274284B2
(en)
|
2006-07-13 |
2012-04-26 |
Janssen Pharmaceutica N.V. |
Mtki quinazoline derivatives
|
CA2662449A1
(en)
|
2006-09-08 |
2008-03-13 |
Bayer Schering Pharma Aktiengesellschaft |
Compounds and methods for 18f labeled agents
|
CA2664118A1
(en)
|
2006-09-21 |
2008-07-03 |
Ambrilia Biopharma Inc. |
Protease inhibitors
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
US20100311767A1
(en)
|
2007-02-27 |
2010-12-09 |
Abbott Gmbh & Co. Kg |
Method for the treatment of amyloidoses
|
WO2008112289A2
(en)
|
2007-03-12 |
2008-09-18 |
Nektar Therapeutics |
Oligomer-protease inhibitor conjugates
|
EP2185562B1
(en)
|
2007-07-27 |
2015-12-02 |
Janssen Pharmaceutica, N.V. |
Pyrrolopyrimidines useful for the treatment of proliferative diseases
|
EP2053033A1
(en)
|
2007-10-26 |
2009-04-29 |
Bayer Schering Pharma AG |
Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
|
EP2100900A1
(en)
|
2008-03-07 |
2009-09-16 |
Universitätsspital Basel |
Bombesin analog peptide antagonist conjugates
|
DK2283024T3
(da)
|
2008-03-10 |
2013-08-05 |
Janssen Pharmaceutica Nv |
4-aryl-2-anilinpyrimidiner som PLK-kinaseinhibitorer
|
US9095620B2
(en)
*
|
2008-03-12 |
2015-08-04 |
Nektar Therapeutics |
Reagents
|
EP2116236A1
(en)
|
2008-04-21 |
2009-11-11 |
Université de Mons-Hainaut |
Bisbenzamidine derivatives for use as antioxidant
|
CN102089318B
(zh)
|
2008-07-08 |
2014-05-21 |
吉里德科学公司 |
Hiv抑制剂化合物的盐
|
PL2364314T3
(pl)
|
2008-12-09 |
2014-08-29 |
Gilead Sciences Inc |
Modulatory receptorów Toll-podobnych
|
US20120135965A1
(en)
*
|
2009-05-20 |
2012-05-31 |
Ranbaxy Laboratories Limited |
Amorphous fosamprenavir calcium
|
WO2010144869A2
(en)
|
2009-06-12 |
2010-12-16 |
Nektar Therapeutics |
Protease inhibitors
|
EP2477996A1
(en)
|
2009-09-16 |
2012-07-25 |
Ranbaxy Laboratories Limited |
Process for the preparation of fosamprenavir calcium
|
WO2011061590A1
(en)
|
2009-11-17 |
2011-05-26 |
Hetero Research Foundation |
Novel carboxamide derivatives as hiv inhibitors
|
EP2501431B1
(en)
|
2009-11-19 |
2020-01-08 |
Wellinq Medical B.V. |
Narrow profile composition-releasing expandable medical balloon catheter
|
WO2011085130A1
(en)
|
2010-01-07 |
2011-07-14 |
Pliva Hrvatska D.O.O. |
Solid state forms of fosamprenavir calcium salt and process for preparation thereof
|
EP3351249A1
(en)
|
2010-01-27 |
2018-07-25 |
VIIV Healthcare Company |
Antiviral therapy
|
US20110223131A1
(en)
|
2010-02-24 |
2011-09-15 |
Gilead Sciences, Inc. |
Antiviral compounds
|
US20110224443A1
(en)
*
|
2010-03-15 |
2011-09-15 |
Venkata Naga Brahmeshwara Rao Mandava |
Preparation of fosamprenavir calcium
|
WO2011114212A1
(en)
|
2010-03-19 |
2011-09-22 |
Lupin Limited |
Ammonium, calcium and tris salts of fosamprenavir
|
JP2013523182A
(ja)
|
2010-04-15 |
2013-06-17 |
アボット・ラボラトリーズ |
アミロイドベータ結合タンパク質
|
WO2011141515A1
(en)
|
2010-05-14 |
2011-11-17 |
Bayer Pharma Aktiengesellschaft |
Diagnostic agents for amyloid beta imaging
|
US20130211108A1
(en)
|
2010-06-18 |
2013-08-15 |
Mylan Laboratories Ltd |
Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts
|
US8785648B1
(en)
|
2010-08-10 |
2014-07-22 |
The Regents Of The University Of California |
PKC-epsilon inhibitors
|
EP2603524A1
(en)
|
2010-08-14 |
2013-06-19 |
AbbVie Inc. |
Amyloid-beta binding proteins
|
EP2614055A2
(en)
*
|
2010-09-10 |
2013-07-17 |
Lupin Limited |
Process for preparation of substantially pure fosamprenavir calcium and its intermediates
|
GB201019043D0
(en)
|
2010-11-10 |
2010-12-22 |
Protea Biopharma N V |
Use of 2',5'-oligoadenylate derivative compounds
|
WO2012085625A1
(en)
|
2010-12-21 |
2012-06-28 |
Lupin Limited |
Process for the preparation of fosamprenavir calcium and intermediate used in its preparation
|
WO2012107937A2
(en)
*
|
2011-02-10 |
2012-08-16 |
Mylan Laboratories Ltd |
Crystalline fosamprenavir calcium and process for the preparation thereof"
|
SG10201800715PA
(en)
|
2011-06-21 |
2018-02-27 |
Alnylam Pharmaceuticals Inc |
Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof
|
WO2012178033A2
(en)
|
2011-06-23 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
US9309213B2
(en)
|
2011-07-11 |
2016-04-12 |
Purdue Research Foundation |
C-3 substituted bicyclooctane based HIV protease inhibitors
|
WO2013011485A1
(en)
|
2011-07-20 |
2013-01-24 |
Ranbaxy Laboratories Limited |
Process for the preparation of sulfonamides useful as retroviral protease inhibitors
|
IN2012DE00082A
(US06559137-20030506-C00183.png)
|
2012-01-10 |
2015-05-01 |
Council Scient Ind Res |
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
EP2700396A3
(en)
|
2012-06-20 |
2015-04-29 |
Sylphar Nv |
Strip for the delivery of oral care compositions
|
WO2014059034A2
(en)
|
2012-10-09 |
2014-04-17 |
President And Fellows Of Harvard College |
Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation
|
US9227990B2
(en)
|
2012-10-29 |
2016-01-05 |
Cipla Limited |
Antiviral phosphonate analogues and process for preparation thereof
|
LT2929031T
(lt)
|
2012-12-05 |
2018-02-12 |
Alnylam Pharmaceuticals, Inc. |
Pcsk9 irna kompozicijos ir jų naudojimo būdai
|
WO2014160129A2
(en)
|
2013-03-14 |
2014-10-02 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
BR112015029139B1
(pt)
|
2013-05-22 |
2022-07-12 |
Alnylam Pharmaceuticals, Inc |
Agente de rnai de fita dupla para inibição da expressão de serpina1 em uma célula, seus usos, bem como composição farmacêutica e método in vitro de inibição da expressão de serpina1 em uma célula
|
CN105452463B
(zh)
|
2013-05-22 |
2019-06-21 |
阿尔尼拉姆医药品有限公司 |
Tmprss6 irna组合物及其使用方法
|
AU2014362262B2
(en)
|
2013-12-12 |
2021-05-13 |
Alnylam Pharmaceuticals, Inc. |
Complement component iRNA compositions and methods of use thereof
|
CN113057959A
(zh)
|
2014-02-11 |
2021-07-02 |
阿尔尼拉姆医药品有限公司 |
己酮糖激酶(KHK)iRNA组合物及其使用方法
|
WO2015175510A1
(en)
|
2014-05-12 |
2015-11-19 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating a serpinc1-associated disorder
|
SG10202104570TA
(en)
|
2014-05-22 |
2021-06-29 |
Alnylam Pharmaceuticals Inc |
Angiotensinogen (agt) irna compositions and methods of use thereof
|
EP3180003B1
(en)
|
2014-07-01 |
2022-01-12 |
The Regents of the University of California |
Pkc-epsilon inhibitors
|
WO2016001907A1
(en)
|
2014-07-02 |
2016-01-07 |
Prendergast Patrick T |
Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
|
AU2015287773B2
(en)
|
2014-07-11 |
2018-03-29 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors for the treatment of HIV
|
EP3191591A1
(en)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
US9738664B2
(en)
|
2014-10-29 |
2017-08-22 |
Wisconsin Alumni Research Foundation |
Boronic acid inhibitors of HIV protease
|
WO2016069694A2
(en)
|
2014-10-30 |
2016-05-06 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
CA2968114A1
(en)
|
2014-11-17 |
2016-05-26 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
WO2016083490A1
(en)
|
2014-11-27 |
2016-06-02 |
Remynd Nv |
Compounds for the treatment of amyloid-associated diseases
|
AU2016219263B2
(en)
|
2015-02-13 |
2022-12-01 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
|
CN107743522B
(zh)
|
2015-04-13 |
2022-11-11 |
阿尔尼拉姆医药品有限公司 |
类血管生成素3(ANGPTL3)iRNA组合物及其使用方法
|
CN108025187A
(zh)
|
2015-04-28 |
2018-05-11 |
新南创新私人有限公司 |
靶向nad+以治疗化学疗法和放射疗法引发的认知损害、神经病变和不活动
|
KR20180002688A
(ko)
|
2015-05-06 |
2018-01-08 |
알닐람 파마슈티칼스 인코포레이티드 |
인자 XII(하게만 인자)(F12), 칼리크레인 B, 혈장(플레처 인자) 1(KLKB1) 및 키니노겐 1(KNG1) iRNA 조성물 및 그의 이용 방법
|
EP3310918B1
(en)
|
2015-06-18 |
2020-08-05 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
WO2017048620A1
(en)
|
2015-09-14 |
2017-03-23 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
|
MA42818A
(fr)
|
2015-09-15 |
2018-07-25 |
Gilead Sciences Inc |
Modulateurs de récepteurs de type toll pour le traitement du vih
|
TWI743069B
(zh)
|
2015-12-07 |
2021-10-21 |
美商健贊公司 |
治療serpinc1相關疾患之方法及組成物
|
JP2018536689A
(ja)
|
2015-12-10 |
2018-12-13 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
ステロール調節エレメント結合タンパク質(SREBP)シャペロン(SCAP)iRNA組成物およびその使用方法
|
EP3469083A1
(en)
|
2016-06-10 |
2019-04-17 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
TWI788312B
(zh)
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
KR20230166146A
(ko)
|
2016-12-16 |
2023-12-06 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스티레틴(TTR) iRNA 조성물을 사용하여 TTR-관련 질병을 치료하거나 예방하는 방법
|
DK3621963T3
(da)
|
2017-05-11 |
2024-04-15 |
Remynd N V |
Forbindelser til behandling af epilepsi, neurodegenerative lidelser og andre CNS-lidelser
|
WO2019016732A1
(en)
|
2017-07-21 |
2019-01-24 |
Viiv Healthcare Company |
REGIMES FOR THE TREATMENT OF HIV AND AIDS INFECTIONS
|
PT3661937T
(pt)
|
2017-08-01 |
2021-09-24 |
Gilead Sciences Inc |
Formas cristalinas de ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofurano-2-il)oxi)metil)(fenoxi)fosforil)-l-alaninato de etil (gs-9131) para tratamento de infeções virais
|
AU2018360697A1
(en)
|
2017-11-01 |
2020-05-14 |
Alnylam Pharmaceuticals, Inc. |
Complement component C3 iRNA compositions and methods of use thereof
|
TW202023574A
(zh)
|
2018-08-13 |
2020-07-01 |
美商阿尼拉製藥公司 |
B型肝炎病毒(HBV)dsRNA劑組合物及其使用方法
|
MX2021008628A
(es)
|
2019-01-16 |
2021-11-17 |
Genzyme Corp |
Composiciones de arni para serpinc1 y metodos de uso de las mismas.
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
WO2021170600A1
(en)
|
2020-02-24 |
2021-09-02 |
Katholieke Universiteit Leuven |
Pyrrolopyridine and imidazopyridine antiviral compounds
|
WO2021209563A1
(en)
|
2020-04-16 |
2021-10-21 |
Som Innovation Biotech, S.A. |
Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
|
JP2024500543A
(ja)
|
2020-12-22 |
2024-01-09 |
ルクセンブルク インスティテュート オブ ヘルス(エルアイエイチ) |
がん及び循環器疾患の処置のための選択的ackr3調節物質としてのコノリジンアナログ
|
EP4301369A1
(en)
|
2021-03-04 |
2024-01-10 |
Universiteit Antwerpen |
Quinazolin-4-one and thieno[2,3-d]pyrimidin-4-one inhibitors of erbb4 (her4) for use in the treatment of cancer
|
EP4347541A2
(en)
|
2021-05-31 |
2024-04-10 |
Telix Pharmaceuticals (Innovations) Pty Ltd |
Improved prostate-specific membrane antigen targeting radiopharmaceuticals and uses thereof
|
WO2023021132A1
(en)
|
2021-08-18 |
2023-02-23 |
Katholieke Universiteit Leuven |
6-substituted- and 6,7-disubstituted-7-deazapurine ribonucleoside analogues
|
WO2023046900A1
(en)
|
2021-09-23 |
2023-03-30 |
Katholieke Universiteit Leuven |
Ribonucleoside analogues against -sars-cov-2
|
WO2023241799A1
(en)
|
2022-06-15 |
2023-12-21 |
Université Libre de Bruxelles |
Flavanols for use in the treatment of retroviral infections
|
WO2024062043A1
(en)
|
2022-09-21 |
2024-03-28 |
Universiteit Antwerpen |
Substituted phenothiazines as ferroptosis inhibitors
|